| Family: | Blackrock (iShares) |
| Name: | iShares Biotechnology ETF |
| Inception Date: | 5-Feb-2001 |
| Termination Date: | |
| Investment Objective: | The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It provides exposure to U.S. companies in the biotechnology industry. |
| Prospectus | |
| Top 10 Holdings | ||
| GILEAD SCIENCES INC | GILD | 9.8049% |
| VERTEX PHARMACEUTICALS INC | VRTX | 9.2111% |
| AMGEN INC | AMGN | 9.0210% |
| REGENERON PHARMACEUTICALS INC | REGN | 6.8592% |
| ALNYLAM PHARMACEUTICALS INC | ALNY | 3.6966% |
| INSMED INC | INSM | 2.6666% |
| ARGENX SE ADR | ARGX | 2.5769% |
| BIOGEN INC | BIIB | 2.4167% |
| NATERA INC | NTRA | 2.2426% |
| UNITED THERAPEUTICS CORP | UTHR | 2.0241% |
| Top 10 Holdings Weight: | 50.5% |
| Number of Holdings: | 260 |
| Shares Outstanding: | 47,500,000 |
| Total Net Assets: | 7,939,150,000 |
| NAV: | 167.15 |
| Net Expense Ratio: | 0.44% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Large & Mid Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
